Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Int Arch Allergy Immunol. 2019 Nov 29;181(1):11–23. doi: 10.1159/000504847

Figure 5. Anti-eosinophil monoclonal antibodies: targeting the IL-5-IL5R-alpha axis.

Figure 5.

Mepolizumab and reslizumab are humanized monoclonal antibodies that target and neutralize circulating IL-5. Both have been approved for clinical use for add-on maintenance treatment of adults with severe eosinophilic asthma. Benralizumab, an antibody in use for similar indications, is directed against the α-chain of the IL-5 receptor (IL-5R) and induces antibody-mediated cellular cytotoxicity (ADCC) in eosinophils, depleting eosinophils both in blood and tissues.